Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | CAMKK2 | Q96RR4 | 3/20 | 0.41 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.41 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.41 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.41 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.41 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.41 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.41 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | CTRC | Q99895 | 1/20 | 0.40 |
| ▸ | MPL | P40238 | 1/20 | 0.39 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.39 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.39 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3332983 | 0.86 | GFER (0.42) | SMN1; SMN2HTTKEAP1CSNK2A2CSNK2B | |
| SCHEMBL3335325 | 0.85 | KDM4E (0.56) | SMN1; SMN2HTTPRKAB2PRKAG1PRKAA2 | |
| SCHEMBL11871562 | 0.74 | CSNK2A2 (0.41) | SMN1; SMN2HTTKEAP1CSNK2A2CSNK2B | |
| SCHEMBL10629956 | 0.73 | HDAC7 (0.47) | SMN1; SMN2CTRCCSNK2A1KDM4EALDH1A1 | |
| SCHEMBL12700386 | 0.73 | HTT (0.44) | SMN1; SMN2HTTCAMKK2PRKAB2PRKAG1 | |
| SCHEMBL13302160 | 0.72 | HTT (0.44) | SMN1; SMN2HTTKEAP1ARCSNK2A2 | |
| SCHEMBL17179425 | 0.72 | AR (0.59) | ARKDM4E | |
| SCHEMBL30771213 | 0.71 | HTT (0.45) | SMN1; SMN2HTTKEAP1CAMKK2AR | |
| SCHEMBL2811213 | 0.71 | HTT (0.59) | SMN1; SMN2HTTKEAP1CSNK2A2CSNK2B | |
| SCHEMBL29415445 | 0.71 | HTT (0.59) | SMN1; SMN2HTTKEAP1CSNK2A2CSNK2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362066-B2 | Compounds and methods for treating protein folding disorders | TREVENTIS CORPORATION (US) | 2013-01-29 | — | — | US | disclosed |
| US-20100144821-A1 | COMPOUNDS AND METHODS FOR TREATING PROTEIN FOLDING DISORDERS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144821-A1 | COMPOUNDS AND METHODS FOR TREATING PROTEIN FOLDING DISORDERS | SNCA, MAPT, APP | SMN1; SMN2 141/4885HTT 5/4885KEAP1 253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.